Applying multimodal AI to physiological waveforms improves genetic prediction of cardiovascular traits

Electronic health records, biobanks, and wearable biosensors enable the collection of multiple health modalities from many individuals. Access to multimodal health data provides a unique opportunity for genetic studies of complex traits because different modalities relevant to a single physiological system (e.g., circulatory system) encode complementary and overlapping information. We propose a multimodal deep learning method, multimodal representation learning for genetic discovery on low-dimensional embeddings (M-REGLE), for discovering genetic associations from a joint representation of complementary electrophysiological waveform modalities. M-REGLE jointly learns a lower representation (i.e., latent factors) of multimodal physiological waveforms using a convolutional variational autoencoder, performs genome-wide association studies (GWASs) on each latent factor, then combines the results to study the genetics of the underlying system. To validate the advantages of M-REGLE and multimodal learning, we apply it to common cardiovascular modalities (photoplethysmogram [PPG] and electrocardiogram [ECG]) and compare its results to unimodal learning methods in which representations are learned from each data modality separately but are statistically combined for downstream genetic comparison. M-REGLE identifies 19.3% more loci on the 12-lead ECG dataset, 13.0% more loci on the ECG lead I + PPG dataset, and its genetic risk score significantly outperforms the unimodal risk score at predicting cardiac phenotypes, such as atrial fibrillation (Afib), in multiple biobanks

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease

The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted as the document was compiled through December 2008. Repeated literature searches were performed by the guideline development staff and writing committee members as new issues were considered. New clinical trials published in peer-reviewed journals and articles through December 2011 were also reviewed and incorporated when relevant. Furthermore, because of the extended development time period for this guideline, peer review comments indicated that the sections focused on imaging technologies required additional updating, which occurred during 2011. Therefore, the evidence review for the imaging sections includes published literature through December 2011